What's New


License Agreement Has Been Entered into with Rege Nephro Co.,Ltd.

We have executed a worldwide license agreement with Rege Nephro Co.,Ltd. (Kyoto, Japan) for development and provision of regenerative medicine products using iPS cell-derived renal progenitor cells. The license allows exclusive rights on patents related to renal progenitor induction technologies and non-exclusive rights on patents related to iPS cell technologies, for which we have been granted with sublicensing rights by Kyoto University.

Rege Nephro Co.,Ltd.

Back to top